help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Endocrinology, doi:10.1210/en.2008-0034
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
149/8/4009    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Google Scholar
Right arrow Articles by Kawano, T.
Right arrow Articles by Insogna, K.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kawano, T.
Right arrow Articles by Insogna, K.
Endocrinology Vol. 149, No. 8 4009-4015
Copyright © 2008 by The Endocrine Society

The Anabolic Response to Parathyroid Hormone Is Augmented in Rac2 Knockout Mice

Tsutomu Kawano, Nancy Troiano, Douglas J. Adams, Jian Jun Wu, Ben-hua Sun and Karl Insogna

Section of Endocrinology (T.K., J.J.W., B.S., K.I.) and Department of Orthopedics (N.T.), Yale School of Medicine, New Haven, Connecticut 06520-8020; and Department of Orthopedics (D.J.A.), University of Connecticut Health Center, Farmington, Connecticut 06030

Address all correspondence and requests for reprints to: Tsutomu Kawano, M.D., Ph.D., Yale School of Medicine, Department of Medicine, Endocrine Section, TAC S130, 333 Cedar Street, New Haven, Connecticut 06520-8020. E-mail: tsutomu.kawano{at}yale.edu.

PTH is the only currently available anabolic therapy for osteoporosis. In clinical practice, the skeletal response to PTH varies and because therapy is limited to 2 yr, approaches to maximize the therapeutic response are desirable. Rac2 is a small GTPase that is expressed only in hematopoietic tissue. Rac2–/– mice have a slight increase in bone mass and osteoclasts isolated from these animals have reduced basal resorptive activity and reduced chemotaxis. To evaluate the anabolic response to PTH in Rac2–/– mice, we treated 18 Rac2–/– and 17 control, age-matched wild-type animals once daily for 28 d with 80 ng/g body weight of h(1–34)PTH. Treatment resulted in significantly greater increments in spinal, femur, and total bone density in the Rac2–/– as compared with wild-type animals. Microcomputed tomography analysis demonstrated greater increases in trabecular thickness and cortical thickness in the knockout mice. Interestingly, histomorphometric analysis showed an equivalent increase in osteoblast and osteoclast number in response to PTH treatment in both groups of animals. However, as judged by changes in serum markers, the resorptive response to PTH was impaired. Thus, telopeptide of type 1 collagen was 15.9 ± 6.9 ng/ml after PTH treatment in the knockout animals and 26.8 ± 11.1 ng/ml in the PTH-treated wild-type group. In contrast, serum aminoterminal propeptide of type 1 collagen and osteocalcin were equivalent in both groups. We conclude that, in the genetic absence of Rac2, the anabolic response to PTH is increased. This appears to be due to attenuated resorptive activity of osteoclasts.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society